TNF-α Blockade by a Dimeric TNF Type I Receptor Molecule Selectively Inhibits Adaptive Immune Responses

References

• Armitage R. J. Tumor Necrosis Factor Receptor Superfamily Members and Their Ligands. Curr. Opin. Immun. 1994; 6: 407
   PubMed Web of Science ®Google Scholar
• Bancroft G. J., Schreiber R. D., Unanue E. R. Natural Immunity: A T-cell Independent Pathway of Macrophage Activation, Defined in the SCID Mouse. Immunol, Rev. 1991; 124: 5
   PubMed Web of Science ®Google Scholar
• Bendtzer K. Why is Too Little TNF Bad?. Cytokine. 1991; 3: 636
   PubMedGoogle Scholar
• Beutler B., Milsark I. W., Cerami A. Passive Immunization Against Cachectin/tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin. Science 1985; 229: 869
   PubMed Web of Science ®Google Scholar
• Bradley S. G., Morahan P. S. Approaches to Assessing Host Resistance. Enviro. Health Persp. 1982; 43: 61
   PubMed Web of Science ®Google Scholar
• Braegger C. P., MacDonald T. T. Immune Mechanisms in Chronic Inflammatory Bowel Disease. Ann. Allergy 1994; 72: 135, 1994
   PubMedGoogle Scholar
• Bromberg J. S., Chavin K. D., Kunkel S. L. Anti-Tumor Necrosis Factor Antibodies Suppress Cell Mediated Immunity in vivo. J. Immunol. 1992; 148: 3412
   PubMed Web of Science ®Google Scholar
• Cassatella M. A. The Production of Cytokmes by Polymorphonuclear Neutrophils. Immuno. Today 1995; 16: 21
   PubMedGoogle Scholar
• Chen W., Havell E. A., Harmsen A. G. Importance of Endogenous Tumor Necrosis Factor Alpha and Gamma Interferon in Host Resistance Against Pneumocystis carinii Infection. Infect. Immun. 1992; 60: 1279
   PubMedGoogle Scholar
• Corcione A., Ottonello L., Tortolina G., Tasso P., Ghiotto F., Airoldi I., Taborelli G., Malavesi F., Dallegri F., Pistoia V. Recombinant Tumor Necrosis Factor Enhances the Locomotion of Memory and Naive B Lymphocytes from Human Tonsils Through the Selective Engagement of the Type II Receptor. Blood 1997; 90: 4493
   PubMedGoogle Scholar
• Dai W., Bartens W., Kohler G., Hufnagel M., Kopf M., Brombacher F. Impaired Macrophage Listericidal and Cytokine Activities are Responsible for the Rapid Death of Listeria monocytogenes-infected IFN-γ Receptor-Deficient Mice. J. Immunol. 1997; 158: 5297
   PubMedGoogle Scholar
• Danis V. A., Franic G. M., Rathjen D. A., Laurent R. M., Brooks P. M. Circulating Cytokine Levels in Patients with Rheumatoid Arthritis: Results of a Double Blind Trial with Sulphasalazine. Ann. Rheum. Dis. 1992; 51: 946
   PubMed Web of Science ®Google Scholar
• Descotes J. Drug-Induced Immune Diseases. Elsevier Science, Amsterdam 1990; 28
   Google Scholar
• Descotes J. in Methods in Immunotoxicology: Popliteal Lymph Node Assay, Burleson. Wiley-Liss, New York 1995; 189
   Google Scholar
• Dinarello C. A. Interleukin-1 and Tumor Necrosis Factor: Effector Cytokines in Autoimmune Diseases. Semin. Immunol. 1992; 4: 133
   PubMedGoogle Scholar
• Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H., Woody J. N. Randomized Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor α (cA2) Versus Placebo in Rheumatoid Arthritis. Lancet 1994; 349: 521
   Google Scholar
• Elsasser-Beile U., von Kleist S., Gerlach S., Gallati H., Schulte J. Monting. Cytolune Production in Whole Blood Cell Cultures of Patients with Crohn's Disease and Ulcerative Colitis. J. Clin. Lab. Analysis 1994; 8: 447
   PubMedGoogle Scholar
• Espat N. J., Cendan J. C., Beierle E. A., Auffenberg T. A., Rosenberg J., Russell D., Kenney J. S., Fischer E., Montegut W., Lowry S. F., Copeland E., Moldawer L. L. PEG-BP-30 Monotherapy Attenuates the Cytokine-Mediated Inflammatory Cascade in Baboon Escherichia coli Septic Shock. J. Surg. Res. 1995; 59: 153
   PubMedGoogle Scholar
• Farahat M. N., Tanni G., Poston R., Panayi G. S. Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis. Ann. Rheum. Dis. 1993; 52: 870
   PubMed Web of Science ®Google Scholar
• Feldmann M., Brennan F. M., Maini R. V. Role of Cytokines in Rheumatoid Arthritis. Annu. Rev. Immunol. 1996; 14: 397
   PubMed Web of Science ®Google Scholar
• Fisher C. J., Agosti J. M., Opal S. M., Lowry S. F., Balk R. A., Sadoff J. D., Abraham E., Schein R. M.H., Benjamin E. Treatment of Septic Shock with the Tumor Necrosis Factor: Fc fusion protein. New Engl. Jour. Med. 1996; 334: 1697
   PubMed Web of Science ®Google Scholar
• Fleshner M., Brennan F. X., Nguyen K. L., Watkins L. R., Maier S. F. RU-486 Blocks Differentially Suppressive Effects of Stress on in vivo Anti-KLH Immunoglobulin Response. Amer. J. Phys. 1996; 271: R1344
   Google Scholar
• Garcia I., Miyazah Y., Aralu K., Lucas R., Grau G. E., Milon G., Belkaid Y., Montixi C., Lesslauer W., Vassalli P. Transgenic Mice Expressing High Levels of Soluble TNF-R1 Fusion Protein are Protected from Lethal Septic Shock and Cerebral Malaria, and are Highly Sensitive to Listeria monocytogenes and Leishmania major Infection. Eur. J. Immun. 1995; 25: 2401
   PubMed Web of Science ®Google Scholar
• Gosselin D., DeSanctis J., Boule M., Skamene E., Matouk C., Radzioch C. Role of Tumor Necrosis Factor Alpha in Innate Resistance to Mouse Pulmonary Infection with Pseudomonas aeruginosa. Infect. Immun. 1995; 63: 3272
   PubMed Web of Science ®Google Scholar
• Hale K. K., Smith C. G., Baker S. L., Vanderslice R. W., Squires C. H., Gleason T. M., Tucker K. K., Kohno T., Russell D. A. D. A. Multifunctional Regulation of the Biological Effects of TNF-α by the Soluble type I and type II TNF Receptors. Cytokine. 1995; 7: 26
   PubMed Web of Science ®Google Scholar
• Havell E. A., Moldawer L. L., Helfgott D., Kilian P., Sehgal B. Type I IL-1 Receptor Blockade Exacerbates Murine Listeriosis. J. Immun. 1992; 148: 1486
   PubMedGoogle Scholar
• Kashiwa H., Wright S. C., Bonavida B. Regulation of B Cell Maturation and Differentiation. J Immun. 1987; 138: 1383
   PubMed Web of Science ®Google Scholar
• Kaufmann S. H. Immunity to Intracellular Microbial Pathogens. Immuno. Today 1995; 17: 338
   Google Scholar
• Kondo S., Wang B., Fujisawa H., Shivji G. M., Echtenacher B., Mak T. W., Sander D. W. Effect of Gene-Targeted Mutation in TNF Receptor (P55) on Contact Hypersensitivity and Ultraviolet B-Induced Immunosuppression. J. Immunol. 1995; 380: 1
   Google Scholar
• Lebrec H., Blot C., Pequet S., Roger P., Bohuon C., Pallardy M. Immunotoxicological Investigation Using Pharmaceutical Drugs: in vivo Evaluation of Immune Effects. Fundam. Appl. Toxicol. 1994; 23: 159
   PubMedGoogle Scholar
• Leclerc C., M-Schutze P., Deriaurd E., Przewlocki G. G. The in vivo Elimination of CD4+ T Cells Prevents the Induction But not the Expression of Carrier-induced Epitopic Suppression. J. Immun. 1990; 145: 1343
   PubMed Web of Science ®Google Scholar
• Lockwood L., Silbert L. H., Fleshner M., Laudenslager M. L., Watkins L. R., Maier S. F. Morphine-Induced Decreases in vivo Antibody Responses. Brain Behav. Immun. 1994; 8: 24
   PubMedGoogle Scholar
• Louie A., Baltch A. L., Smith R. P., Franke M. A., Ritz W. J., Singh J. K., Gordon M. A. Tumor Necrosis Factor Alpha has a Protective Role in a Murine Model of Systemic Candidiasis. Infect. Immun. 1994; 62: 2761
   PubMedGoogle Scholar
• Luster M. I., Munson A. E., Thomas P. T., Holsapple M. P., Fenters J. D., White K. L., Lauer L. D., Germolec D. R., Rosenthal G. J., Dean J. H. Development of a Testing Battery to Assess Chemical-Induced Immunotoxicity: National Toxicology Program's Guidelines for Immunotoxicity Evaluation in Mice. Fundam. Appl. Toxicol. 1988; 10: 2
   PubMedGoogle Scholar
• Luster M. I., Portier C., Pait D. G., Germolec D. R. Use of Animal Studies in Risk Assessment for Immunotoxicology. Toxicology 1994; 92: 229
   PubMedGoogle Scholar
• Luster M. I., Portier C., Pait D. G., Rosenthal G. J., Germolec D. R., Corsini E., Blaylock B. L., Pollock P., Kouchi Y., Craig W., White K. L., Munson A. E., Comment C. E. Risk Asessment in Immunotoxicology. Fundam. Appl. Toxicol. 1993; 21: 71
   PubMedGoogle Scholar
• Moreland L. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein. New Engl. Jour. Med. 1997; 337: 141
   PubMed Web of Science ®Google Scholar
• Morsy T. A., El Missiry A. G., Sarwat M. A., El Rassed M. M., Habib F. S.M., Abou Gamra M. M. Tumor Necrosis Factor-Alpha (cachectin) in Human Visceral Leishmaniasis. J. Egypt. Soc. Parasitol. 1995; 25: 31
   PubMedGoogle Scholar
• Nakane A., Numata A., Minagawa T. Suppression of Host Resistance Against Listeria monocytogenes Infection by 15-Deoxyspergualin in Mice. Immunol. 1990; 71: 560
   PubMedGoogle Scholar
• Pfeffer K., Matsuyama T., Kundig T. M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P. S., Kronke M., Mak T. W. Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor are Resistance to Endotoxic Shock, yet Succumb tom L. monocytogenes. Infection. Cell 1993; 73: 457
   Google Scholar
• Rouveix B. Opiates and Immune Function. Therapie. 1992; 47: 503
   PubMed Web of Science ®Google Scholar
• Russell D. A., Tucker K. K., Chinookoswong N., Thompson R. C., Kohno T. Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function. J. Infect. Dis. 1995; 171: 1528
   PubMed Web of Science ®Google Scholar
• Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine. 1995; 7: 251
   PubMed Web of Science ®Google Scholar
• Stack W. A., Mann S. D., Roy A. J., Heath P., Sopwith M., Freeman J., Holmes G., Long R., Forbes A., Kamm M. A., Hawkey C. J. Randomised Controlled Trial of CDP571 Antibody to Tumour Necrosis Factor-α in Crohn's Disease. Lancet 1997; 349: 521
   PubMed Web of Science ®Google Scholar
• Thomas C., Groten J., Kammuller M., De Bakker J. M., Seinen W., Bloksma N. Popliteal Lymph Node Reaction in Mice Induced by the Drug Zimeldine. Int. J. Immunopharm. 1989; 11: 693
   PubMedGoogle Scholar
• Thorne P., Hawk C., Kaliszewski S. The Non-Invasive MEST Assay: I: Refinements for Detecting Weak Contact Sensitizers. Fund. Appl. Toxic. 1991; 17: 790
   PubMedGoogle Scholar
• van Furth R., van Zwet T. L., Buisman A. M., van Dissel J. T. Anti-Tumor Necrosis Factor Antibodies Inhibit the Influx of Granulocytes and Monocytes into an Iinflammatory Exudate and Enhance the Growth of Listeria monocytogenes in Various Organs. J Infect. Dis. 1994; 170: 234
   PubMedGoogle Scholar
• White K. L., Krasula R. W., Munson A. E., Holsapple M. P. Effects of Hydroxyethylstarch (HespanR) a Plasma Expander, on the Functional Activity of the Reticuloendothelial System. Drug Chem. Toxicol. 1986; 9: 305
   PubMed Web of Science ®Google Scholar
• Wicks I., Mc G., Coll G., Harrison L. New Perspectives on Rheumatoid Arthritis. Immun. Today 1994; 15: 553
   PubMedGoogle Scholar